Cell Line News and Research

RSS

Enisamium shows potential as antiviral therapy for COVID-19

Researchers studied the effect of enisamium on the growth and proliferation of Caco-2 and normal human bronchial epithelial cells.

6 Oct 2021

SARS-CoV-2 emerging variants display enhanced syncytia formation

Researchers compared the replication and syncytia forming potential of Alpha, Beta, and D614G strains in human cell lines and primary airway cells.

6 Oct 2021

Cysteamine inhibits SARS-CoV-2 variants of concern in vitro

Researchers in the United States have shown that a compound currently used to treat cystinosis exhibits broad antiviral activity against variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

5 Oct 2021

Mandatory vaccines for health care workers might upend nurses’ training

Kaitlyn Hevner expects to complete a 15-month accelerated nursing program at the University of North Florida in Jacksonville in December. For her clinical training this fall, she's working 12-hour shifts on weekends with medical-surgical patients at a hospital.

4 Oct 2021

New analysis reveals distinct differences between molecular profiles of 3D and 2D cultured cells

Oncotarget published "Comparative microsomal proteomics of a model lung cancer cell line NCI-H23 reveals distinct differences between molecular profiles of 3D and 2D cultured cells" which reported that to ascertain phenotypical differences between these two distinct culture conditions, these authors carried out a comparative proteomic analysis of a membrane fraction obtained from 3D- and 2D-cultured NSCLC model cell line NCI-H23.

29 Sep 2021

Human coronavirus replicates in bats without using the spike protein

Researchers in Singapore have conducted a study showing active replication of a human coronavirus in bats that occurred without the viral spike protein binding to host cell receptors.

28 Sep 2021

Study shows how SARS-CoV-2 viral proteases can be targeted to stop virus replication

Researchers at the University of Liverpool have shown how SARS-CoV-2 viral proteases attack the host cell, and how this can be targeted to stop virus replication in cell culture using existing drugs.

21 Sep 2021

A novel FACS-based approach for SARS-CoV-2 serology

A recent study discusses a simple, sensitive, and quantitative serological test based on FACS assay to evaluate antibodies against SARS-CoV-2.

20 Sep 2021

Research on SARS-CoV-2 and dendritic cells may explain why virus is so virulent

In a recent study released on the bioRxiv* preprint server, the researchers suggest that an aberrant inflammatory reaction associated with COVID-19 could be a result of escape from direct sensing by toll-like receptors (TLRs). Moreover, the researchers indicate that this phenomenon might underlie the lack of efficient immunity to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) early during infection.

20 Sep 2021

New SARS-CoV-2 mechanism of host gene suppression

A new study finds that the viral non-coding RNA dubbed vmiR-5p, derived from the viral gene ORF7a, appears to reduce host transcription.

13 Sep 2021

Efficient non-neutralizing antibody to SARS-CoV-2 spike NTD that operates via Fc receptor-mediated pathway

This study revealed that the CV3-13 antibody can mediate Fc effector functions against S protein-expressing cells.

13 Sep 2021

New vaccinia-based COVID-19 vaccine candidate induces robust, durable immune responses

Researchers in Australia have developed a coronavirus disease 2019 (COVID-9) vaccine that induced robust and long-lived humoral and cellular immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in both young and aging mice.

8 Sep 2021

New research has implications for developing cancer therapies targeting mutant p53 protein

The tumor suppressor protein p53 is mutated in more than half of all human cancers. Several drugs that potentially can restore mutant p53 to its normal cancer-killing function are in clinical investigation.

31 Aug 2021

Combination therapy disables PI3K/Akt/mTOR pathway and induces apoptosis in carcinoid syndrome

Oncotarget published "Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosis" which reported that microscopic imaging, immunocytochemistry, wound healing assay, caspase-cleaved cytokeratin 18 CytoDeath ELISA assay, immunofluorescence labeling assays for apoptosis, hypoxia, Western Blotting, Tunnel assay, measurement of 5-HT secretion by carbon fiber amperometry assay, quantitative methylation-specific PCR, morphologic changes, cell viability, apoptosis activity and the expression levels of phospho-Akt1, Akt1, HIF-1α, PI3K, p21, CAIX, 5-HT, phospho-mTOR, and mTOR in xenografts derived from typical H727 and atypical H720 BC cell lines.

28 Aug 2021

Aston University secures KTP project to assist Catalent in developing orally disintegrating tablets

Aston University researchers based in the College of Health and Life Sciences have been awarded a Knowledge Transfer Partnership (KTP) project by Innovate UK, to bring its academic and scientific expertise to assist Catalent in the development of its Zydis® technology, the leading orally disintegrating tablet (ODT).

27 Aug 2021

Compounds from medicinal mushrooms may be our future weapon against SARS-CoV-2

Certain steroid-like compounds from Taiwan's endemic medicinal mushrooms (known as antcins) may inhibit a host cell receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and, thus, prevent viral infection and subsequent development of the coronavirus disease (COVID-19), reports a new study published in the MDPI's journal Plants.

24 Aug 2021

Scientists develop a new way to deliver molecular therapies to cells

Researchers from MIT, the McGovern Institute for Brain Research at MIT, the Howard Hughes Medical Institute, and the Broad Institute of MIT and Harvard have developed a new way to deliver molecular therapies to cells.

19 Aug 2021

White-tailed deer are highly susceptible to SARS-CoV-2 infection

The SARS-CoV-2 virus has been shown to infect a wide range of animals naturally and experimentally, and prior studies indicate deer are susceptible to infection. White-tailed deer (Odocoileus virginianus) fawns have been found to be susceptible to SARS-CoV-2.

19 Aug 2021

ERS Genomics and Cellular Engineering Technologies Enter CRISPR/Cas9 License Agreement

ERS Genomics Limited and Cellular Engineering Technologies today announced a non-exclusive license agreement.

17 Aug 2021

Data reinforces SAB-185’s potential to neutralize SARS-CoV-2 variants

A study, available on the pre-print server bioRxiv*, evaluated the neutralizing capacity of a fully human polyclonal antibody (SAB-185) against the Delta, Kappa, and Lambda variants using a lentiviral-based pseudovirus assay.